ARTICLE | Company News
Metabasis endocrine, metabolic news
June 1, 2009 7:00 AM UTC
Metabasis reduced headcount for the third time in seven months to conserve cash. The company will reduce headcount by 45 (87%) to seven. The remaining employees will assist the company's Board in evaluating and implementing strategic alternatives for MB07803, a second-generation fructose 1,6-bisphosphatase inhibitor in Phase II testing to treat Type II diabetes. Metabasis also has MB07811, a HepDirect prodrug of a thyroid hormone receptor beta agonist in Phase II testing for hypercholesterolemia. ...